Skip to main content

Plasma Protein Binding (PPB) evaluation for GalNAc-conjugated small interfering RNA (siRNA)

The plasma protein binding (PPB) evaluation for GalNAc-conjugated small interfering RNA (siRNA) is an important parameter in understanding its pharmacokinetics (PK), distribution, and clearance from the body. GalNAc-siRNAs are designed for targeted delivery to hepatocytes via the asialoglycoprotein receptor (ASGPR), but their interaction with plasma proteins can impact their bioavailability and efficacy.

Key Considerations in PPB Evaluation of GalNAc-siRNA

  1. Purpose of Plasma Protein Binding (PPB) Evaluation

    • Distribution: Determines the extent to which the siRNA is free in plasma vs. bound to proteins, impacting its availability for hepatocyte targeting.
    • Clearance: High protein binding often reduces renal clearance, prolonging circulation time, while low protein binding may lead to rapid clearance.
    • Efficacy and Safety: Protein binding influences the siRNA’s pharmacodynamic (PD) effect by modulating its free fraction available for receptor binding.

  2. Methodology for PPB Evaluation

    • Equilibrium Dialysis or Ultrafiltration: These techniques are used to assess the free (unbound) fraction of siRNA in plasma. Both methods are widely accepted, but each has distinct benefits:
      • Equilibrium Dialysis: This technique is highly effective for small molecules and siRNAs with lower protein binding. It involves separating free drug from bound drug across a semipermeable membrane.
      • Ultrafiltration: Useful for GalNAc-siRNAs if they exhibit high protein binding, as it allows quick separation of bound and unbound fractions.
    • Surface Plasmon Resonance (SPR) or Isothermal Titration Calorimetry (ITC): These are advanced methods used to directly characterize binding kinetics and affinity with specific plasma proteins, such as albumin.

  3. Common Plasma Proteins Binding GalNAc-siRNA

    • Albumin: Major protein in plasma, often binds GalNAc-conjugated molecules, which can stabilize and prolong circulation.
    • α-1 Acid Glycoprotein and Lipoproteins: Although they bind at lower affinities than albumin, they still contribute to overall PPB, especially in cases of variable protein levels (e.g., disease states).
    • Binding Affinity to ASGPR: Specific to GalNAc conjugates, which are designed for receptor-mediated endocytosis into hepatocytes, ensuring targeted liver delivery.

  4. Interpreting Results and Impact on PK/PD

    • High Protein Binding: When protein binding exceeds 95%, it suggests a smaller fraction of free siRNA in circulation, potentially reducing hepatocyte uptake and ASGPR interaction.
    • Moderate to Low Protein Binding: Greater free fraction may increase clearance and hepatocyte uptake, potentially enhancing therapeutic efficacy but reducing circulation time.
    • Target Organ Delivery: For GalNAc-siRNA, moderate PPB that allows selective ASGPR binding without excessive clearance is optimal for targeting hepatocytes.

  5. Challenges in PPB Evaluation of siRNA

    • Non-covalent Interactions: siRNA can have dynamic interactions with various plasma proteins that may vary based on formulation, conjugation, and physicochemical properties.
    • Stability: GalNAc-siRNAs must be stable in plasma for accurate PPB measurements, as degradation can skew results.
    • Method Sensitivity: As siRNAs are relatively large and complex molecules, sensitivity in detecting free vs. bound fractions is crucial to avoid underestimating protein binding.

Summary

The PPB evaluation of GalNAc-siRNAs is essential in understanding their distribution, clearance, and efficacy in hepatocyte targeting. Utilizing methods like equilibrium dialysis and ultrafiltration provides insights into binding dynamics, while interpreting binding data helps optimize dosing, therapeutic window, and targeted delivery to the liver 

Popular posts from this blog

Human Genome Editing: FDA Draft Guidance Summary

Consideration for Developing Gene Editing Product  1. Genome Editing Methods: Genome editing can be achieved through nuclease-dependent or nuclease-independent methods. Nuclease-dependent methods involve introducing site-specific breaks in DNA using technologies like zinc finger nucleases (ZFNs), transcription activator-like effector nucleases (TALENs), modified-homing endonucleases, and CRISPR-associated (Cas) nucleases. These breaks can lead to modification of the DNA sequence at the cleavage site. Nuclease-independent methods can change DNA sequences without cleaving the DNA and include techniques like base editing and synthetic triplex-forming peptide nucleic acids. The choice of GE technology should consider factors such as the mechanism of action, the ability to target specific DNA sequences, and the potential to optimize components for efficiency, specificity, or stability. 2. Type and Degree of Genomic Modification: Different GE approaches rely on DNA repair pathways such a...
Read more

Stem loop RT-PCR for Detection of siRNA in Animal Tissues

Step Loop RT-PCR for Detection of Small Interfering RNA (siRNA) The recent publications described a novel used the novel method for the detection of siRNAs using a TaqMan®-based approach. This approach utilizes similar strategy that has been used for microRNA detection. The approach is illustrated in below.  In brief, the RT step occurs in the presence of a stem-loop RT primer that is complementary to the last 6–10 bases of the 3′ end of the antisense strand of the target siRNA. The stem-loop primer contains an additional universal sequence at the 5′ end that facilitates a TaqMan-based detection strategy in the subsequent qPCR step. As in the case of microRNA, the forward primer for qPCR is sequence-specific for the target siRNA. For sequence compositions that yield a low predicted melting temperature (Tm), the forward primer is designed as a tailed primer to help increase Tm. Stem Loop PCR for SiRNA Detection Step 1: Preparation of liver and plasma samples for the quanti...
Read more

Human Gene Therapy for Neurodegenerative Diseases: FDA Guidance Summary

  Neurodegenerative diseases are a diverse group of disorders characterized by the progressive degeneration of the central or peripheral nervous system, and they can have various causes and clinical characteristics. This guidance document is a resource for sponsors on different aspects of product development, preclinical testing, and clinical trial design. It acknowledges the unique challenges and considerations associated with developing GT products for such complex and varied diseases. Below are the key summaries from the guidance. CONSIDERATIONS FOR CHEMISTRY, MANUFACTURING AND CONTROLS (CMC) The considerations for Chemistry, Manufacturing, and Controls (CMC) when developing gene therapy (GT) products for the treatment of neurodegenerative diseases are crucial for ensuring the safety and efficacy of these advanced therapies. Here, we will elaborate on the specific CMC considerations outlined in your text: Route of Administration and Product Volume: Neurodegenerative diseases oft...
Read more

FDA Guidance on Studying Multiple Versions of Cellular or Gene Therapy Products in Early-Phase Clinical Trials

 The purpose of this guidance is to offer advice to sponsors interested in conducting early-phase clinical trials for a single disease involving multiple variations of a cellular or gene therapy product. Sponsors aim to gather preliminary safety and efficacy data for these product variations within a single clinical trial. It's important to note that even though multiple product versions are studied together, each version is distinct and typically requires a separate investigational new drug application (IND) submission to the FDA. The primary goal of these early-phase clinical studies is to inform decisions about which product version(s) should be advanced for further development in later-phase trials. As such, these studies are not designed to provide the main evidence of effectiveness needed for a marketing application. They are generally not statistically powered to demonstrate a significant difference in efficacy between the different study arms. In this guidance, the FDA prov...
Read more

ICH Q8 (R2) Pharmaceutical development (CHMP/ICH/167068/04)

 ICH Q8 (R2) is a guideline titled "Pharmaceutical Development" (CHMP/ICH/167068/04). This guideline is part of the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) and provides recommendations for the pharmaceutical development of medicinal products. It offers a structured approach to the development of pharmaceutical products to ensure their quality, safety, and efficacy. Here's an elaboration of ICH Q8 (R2): 1. Purpose of ICH Q8 (R2): The primary purpose of ICH Q8 (R2) is to provide a systematic and science-based approach to pharmaceutical development. The guideline aims to facilitate the design and development of high-quality pharmaceutical products that meet the needs of patients and regulatory authorities. 2. Scope: ICH Q8 (R2) applies to the development of all types of pharmaceutical products, including small molecules, biotechnological products, and other complex medicinal products. 3. Pharmaceutical Develop...
Read more